Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.35 |
| ▸ | CLK2 | P49760 | 3/20 | 0.35 |
| ▸ | CLK3 | P49761 | 3/20 | 0.35 |
| ▸ | KIT | P10721 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 3/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776017 | 0.95 | GSK3B (0.38) | GSK3BMAPTKCNH2HRH3DYRK1A | |
| SCHEMBL16776236 | 0.89 | PRMT5 (0.38) | GSK3BDYRK1ACLK2CLK3PRMT5 | |
| SCHEMBL16776261 | 0.86 | ABL1 (0.37) | GSK3BDYRK1ACLK2CLK3ABL1 | |
| SCHEMBL16776145 | 0.86 | TRPV3 (0.35) | DYRK1ACLK2CLK3 | |
| SCHEMBL16776238 | 0.85 | ABL1 (0.37) | ABL1PRMT5WDR77 | |
| SCHEMBL16776115 | 0.85 | PIM1 (0.34) | DYRK1ACLK2CLK3 | |
| SCHEMBL16776054 | 0.84 | PRMT5 (0.35) | GSK3BDYRK1AKITPRMT5WDR77 | |
| SCHEMBL16775854 | 0.84 | SLC5A1 (0.37) | MAPT | |
| SCHEMBL19365369 | 0.82 | GSK3B (0.38) | GSK3BMAPTKCNH2HRH3DYRK1A | |
| SCHEMBL16776198 | 0.82 | GRM5 (0.39) | GSK3BKCNH2HRH3DYRK1AABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GSK3B 1728/4885MAPT 267/4885KCNH2 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.